Literature DB >> 11422014

Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

A S Gross1, A J McLachlan, I Minns, J B Beal, S E Tett.   

Abstract

AIMS: Previous studies suggest that estimated creatinine clearance, the conventional measure of renal function, does not adequately reflect changes in renal drug handling in some patients, including the immunosuppressed. The aim of this study was to develop and validate a cocktail of markers, to be given in a single administration, capable of detecting alterations in the renal elimination pathways of glomerular filtration, tubular secretion and tubular reabsorption.
METHODS: Healthy male subjects (n = 12) received intravenously infused 2500 mg sinistrin (glomerular filtration) and 440 mg p-aminohippuric acid (PAH; anion secretion), and orally administered 100 mg fluconazole (reabsorption) and 15 mg rac-pindolol (cation secretion). The potential interaction between these markers was investigated in a pharmacokinetic study where markers (M) or fluconazole (F) were administered alone or together (M + F). Validated analytical methods were used to measure plasma and urine concentrations in order to quantify the renal handling of each marker. Plasma protein binding of fluconazole was measured by ultrafiltration. All subjects had an estimated creatinine clearance within the normal range. The renal clearance of each marker (mean+/- s.d.) was calculated as the ratio of the amount excreted in urine and the area-under-the-concentration-time curve. Statistical comparisons were made using a paired t-test and 95% confidence intervals were reported.
RESULTS: The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).
CONCLUSIONS: This study found no interaction between markers and fluconazole in healthy male subjects, suggesting that a single administration of this cocktail of markers of different renal processes can be used to simultaneously investigate pathways of renal drug elimination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422014      PMCID: PMC2014485          DOI: 10.1046/j.1365-2125.2001.01390.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

Review 1.  Renal transport of organic anions.

Authors:  F Roch-Ramel
Journal:  Curr Opin Nephrol Hypertens       Date:  1998-09       Impact factor: 2.894

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

4.  Effects of pindolol on renal function.

Authors:  E Wainer; G Boner; J B Rosenfeld
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

5.  Simultaneous tubular excretion and reabsorption of pindolol in man.

Authors:  L Balant; K Muir; P Dayer; A Gorgia; J L Eberlin; J Estreicher; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine.

Authors:  K Chan; J O Miners; D J Birkett
Journal:  J Chromatogr       Date:  1988-04-08

7.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

8.  Creatinine clearance in renal disease. A reappraisal.

Authors:  K E Kim; G Onesti; O Ramirez; A N Brest; C Swartz
Journal:  Br Med J       Date:  1969-10-04

9.  Effect of pindolol and propranolol on renal function of patients with hypertension.

Authors:  A Pasternack; P Pörsti; L Pöyhönen
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

10.  A new dosing regimen in renal insufficiency: application to cephalexin.

Authors:  R Hori; K Okumura; H Nihira; H Nakano; K Akagi; A Kamiya
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  13 in total

Review 1.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

2.  GFR may not accurately predict aspects of proximal tubule drug handling.

Authors:  T L Putt; Stephen B Duffull; J B W Schollum; R J Walker
Journal:  Eur J Clin Pharmacol       Date:  2014-08-20       Impact factor: 2.953

3.  Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.

Authors:  Antonia Brings; Marie-Louise Lehmann; Kathrin I Foerster; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; David Czock
Journal:  Br J Clin Pharmacol       Date:  2019-05-09       Impact factor: 4.335

4.  Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis.

Authors:  Yu Kyong Kim; Juyoung Lee; Jaeseong Oh; Su-Jin Rhee; Seung Han Shin; Seo Hyun Yoon; SeungHwan Lee; Han-Suk Kim; Kyung-Sang Yu
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

5.  Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Authors:  Pier Giorgio Cojutti; Manuela Lugano; Elda Righi; Giorgio Della Rocca; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-07-21       Impact factor: 2.953

6.  Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.

Authors:  Juliana F Roos; Carl M J Kirkpatrick; Susan E Tett; Andrew J McLachlan; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

7.  Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.

Authors:  Shirin S Joseph; James A Lynham; Peter Molenaar; Andrew A Grace; William H Colledge; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-08       Impact factor: 3.000

Review 8.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

10.  An Improved Vascularized, Dual-Channel Microphysiological System Facilitates Modeling of Proximal Tubular Solute Secretion.

Authors:  Alenka Chapron; Brian D Chapron; Dale W Hailey; Shih-Yu Chang; Tomoki Imaoka; Kenneth E Thummel; Edward Kelly; Jonathan Himmelfarb; Danny Shen; Catherine K Yeung
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.